BioNTech Capex To Depreciation vs Ev To Sales Analysis

BNTX Stock

USD 103.91 0.76 0.73%

BioNTech financial indicator trend analysis is way more than just evaluating BioNTech SE prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BioNTech SE is a good investment. Please check the relationship between BioNTech Capex To Depreciation and its Ev To Sales accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

Capex To Depreciation vs Ev To Sales

Capex To Depreciation vs Ev To Sales Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BioNTech SE Capex To Depreciation account and Ev To Sales. At this time, the significance of the direction appears to have strong relationship.

The correlation between BioNTech's Capex To Depreciation and Ev To Sales is 0.68. Overlapping area represents the amount of variation of Capex To Depreciation that can explain the historical movement of Ev To Sales in the same time period over historical financial statements of BioNTech SE, assuming nothing else is changed. The correlation between historical values of BioNTech's Capex To Depreciation and Ev To Sales is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capex To Depreciation of BioNTech SE are associated (or correlated) with its Ev To Sales. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ev To Sales has no effect on the direction of Capex To Depreciation i.e., BioNTech's Capex To Depreciation and Ev To Sales go up and down completely randomly.

Correlation Coefficient

0.68

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Capex To Depreciation

The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Most indicators from BioNTech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BioNTech SE current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

At this time, BioNTech's Sales General And Administrative To Revenue is fairly stable compared to the past year. Enterprise Value is likely to rise to about 3 B in 2025, despite the fact that Tax Provision is likely to grow to (11.8 M).

	2022	2023	2024	2025 (projected)
Interest Expense	18.9M	569.9K	12.6M	14.7M
Depreciation And Amortization	121.1M	183.4M	298M	312.9M

Interest Expense Depreciation And Amortization

BioNTech fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Total Equity	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Long Term Investments	Property Plant And Equipment Gross	Total Current Assets
Total Assets		0.8	0.93	0.89	1.0	0.97	0.59	-0.93	0.99	0.93	0.94	0.89	0.73	0.95	0.62	0.84	0.67	0.78	0.71	0.88	0.87	0.81	0.9	0.79	0.95	0.95
Short Long Term Debt Total	0.8		0.84	0.9	0.78	0.78	0.83	-0.65	0.74	0.75	0.66	0.67	0.49	0.65	0.71	0.62	0.84	0.53	0.65	0.87	0.73	0.95	0.9	0.53	0.75	0.82
Other Current Liab	0.93	0.84		0.92	0.92	0.9	0.51	-0.82	0.9	0.84	0.83	0.76	0.46	0.82	0.73	0.69	0.68	0.65	0.53	0.88	0.68	0.87	0.91	0.62	0.87	0.89
Total Current Liabilities	0.89	0.9	0.92		0.87	0.79	0.54	-0.74	0.84	0.73	0.74	0.64	0.47	0.7	0.87	0.58	0.71	0.49	0.63	0.99	0.75	0.9	1.0	0.5	0.75	0.94
Total Stockholder Equity	1.0	0.78	0.92	0.87		0.97	0.58	-0.94	1.0	0.94	0.95	0.9	0.75	0.96	0.58	0.85	0.66	0.79	0.71	0.87	0.87	0.79	0.88	0.81	0.95	0.94
Property Plant And Equipment Net	0.97	0.78	0.9	0.79	0.97		0.67	-0.9	0.97	0.99	0.91	0.97	0.77	0.97	0.45	0.93	0.69	0.89	0.73	0.76	0.81	0.76	0.81	0.89	1.0	0.86
Current Deferred Revenue	0.59	0.83	0.51	0.54	0.58	0.67		-0.5	0.56	0.7	0.51	0.69	0.66	0.58	0.23	0.69	0.74	0.6	0.73	0.52	0.69	0.72	0.58	0.62	0.67	0.56
Net Debt	-0.93	-0.65	-0.82	-0.74	-0.94	-0.9	-0.5		-0.95	-0.85	-1.0	-0.84	-0.74	-0.96	-0.4	-0.77	-0.59	-0.7	-0.6	-0.75	-0.89	-0.71	-0.75	-0.74	-0.86	-0.9
Retained Earnings	0.99	0.74	0.9	0.84	1.0	0.97	0.56	-0.95		0.94	0.96	0.91	0.77	0.97	0.54	0.87	0.63	0.81	0.72	0.84	0.87	0.75	0.86	0.83	0.95	0.93
Accounts Payable	0.93	0.75	0.84	0.73	0.94	0.99	0.7	-0.85	0.94		0.87	0.99	0.8	0.95	0.38	0.97	0.67	0.94	0.77	0.7	0.79	0.7	0.76	0.94	1.0	0.81
Cash	0.94	0.66	0.83	0.74	0.95	0.91	0.51	-1.0	0.96	0.87		0.85	0.74	0.97	0.41	0.79	0.6	0.72	0.6	0.75	0.89	0.72	0.75	0.76	0.88	0.9
Non Current Assets Total	0.89	0.67	0.76	0.64	0.9	0.97	0.69	-0.84	0.91	0.99	0.85		0.87	0.95	0.26	0.99	0.6	0.97	0.79	0.62	0.79	0.61	0.68	0.98	0.98	0.76
Non Currrent Assets Other	0.73	0.49	0.46	0.47	0.75	0.77	0.66	-0.74	0.77	0.8	0.74	0.87		0.82	0.11	0.88	0.45	0.81	0.86	0.51	0.86	0.43	0.53	0.88	0.78	0.66
Cash And Short Term Investments	0.95	0.65	0.82	0.7	0.96	0.97	0.58	-0.96	0.97	0.95	0.97	0.95	0.82		0.33	0.92	0.59	0.87	0.7	0.69	0.85	0.67	0.73	0.9	0.96	0.85
Net Receivables	0.62	0.71	0.73	0.87	0.58	0.45	0.23	-0.4	0.54	0.38	0.41	0.26	0.11	0.33		0.19	0.49	0.12	0.31	0.88	0.43	0.72	0.84	0.11	0.41	0.69
Good Will	0.84	0.62	0.69	0.58	0.85	0.93	0.69	-0.77	0.87	0.97	0.79	0.99	0.88	0.92	0.19		0.54	0.98	0.82	0.55	0.75	0.55	0.62	0.99	0.96	0.69
Common Stock Total Equity	0.67	0.84	0.68	0.71	0.66	0.69	0.74	-0.59	0.63	0.67	0.6	0.6	0.45	0.59	0.49	0.54		0.46	0.42	0.68	0.64	0.73	0.7	0.47	0.66	0.68
Short Term Investments	0.78	0.53	0.65	0.49	0.79	0.89	0.6	-0.7	0.81	0.94	0.72	0.97	0.81	0.87	0.12	0.98	0.46		0.75	0.45	0.62	0.44	0.53	0.99	0.93	0.6
Non Current Liabilities Total	0.71	0.65	0.53	0.63	0.71	0.73	0.73	-0.6	0.72	0.77	0.6	0.79	0.86	0.7	0.31	0.82	0.42	0.75		0.63	0.79	0.58	0.69	0.79	0.75	0.71
Inventory	0.88	0.87	0.88	0.99	0.87	0.76	0.52	-0.75	0.84	0.7	0.75	0.62	0.51	0.69	0.88	0.55	0.68	0.45	0.63		0.79	0.88	0.99	0.47	0.72	0.95
Other Current Assets	0.87	0.73	0.68	0.75	0.87	0.81	0.69	-0.89	0.87	0.79	0.89	0.79	0.86	0.85	0.43	0.75	0.64	0.62	0.79	0.79		0.74	0.78	0.7	0.78	0.89
Other Stockholder Equity	0.81	0.95	0.87	0.9	0.79	0.76	0.72	-0.71	0.75	0.7	0.72	0.61	0.43	0.67	0.72	0.55	0.73	0.44	0.58	0.88	0.74		0.9	0.44	0.71	0.85
Total Liab	0.9	0.9	0.91	1.0	0.88	0.81	0.58	-0.75	0.86	0.76	0.75	0.68	0.53	0.73	0.84	0.62	0.7	0.53	0.69	0.99	0.78	0.9		0.54	0.77	0.95
Long Term Investments	0.79	0.53	0.62	0.5	0.81	0.89	0.62	-0.74	0.83	0.94	0.76	0.98	0.88	0.9	0.11	0.99	0.47	0.99	0.79	0.47	0.7	0.44	0.54		0.93	0.63
Property Plant And Equipment Gross	0.95	0.75	0.87	0.75	0.95	1.0	0.67	-0.86	0.95	1.0	0.88	0.98	0.78	0.96	0.41	0.96	0.66	0.93	0.75	0.72	0.78	0.71	0.77	0.93		0.83
Total Current Assets	0.95	0.82	0.89	0.94	0.94	0.86	0.56	-0.9	0.93	0.81	0.9	0.76	0.66	0.85	0.69	0.69	0.68	0.6	0.71	0.95	0.89	0.85	0.95	0.63	0.83

Click cells to compare fundamentals

BioNTech Account Relationship Matchups

BioNTech fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	2.3B	15.8B	23.3B	23.0B	22.5B	23.7B
Short Long Term Debt Total	240.2M	301.5M	212.2M	219.1M	254.2M	175.4M
Other Current Liab	488.5M	1.6B	2.0B	810.3M	1.8B	1.8B
Total Current Liabilities	606.0M	3.5B	3.0B	2.1B	2.5B	1.5B
Total Stockholder Equity	1.4B	11.9B	20.1B	20.2B	19.4B	20.4B
Other Liab	205.6M	97.1M	109.7M	283.9M	326.5M	166.9M
Net Tangible Assets	179.6M	406.5M	1.2B	11.7B	13.5B	14.1B
Property Plant And Equipment Net	326.0M	520.4M	821.1M	971.6M	1.2B	1.2B
Current Deferred Revenue	391.5M	189.1M	76.9M	353.6M	294.9M	192.7M
Net Debt	(970.0M)	(1.4B)	(13.7B)	(11.4B)	(9.5B)	(9.0B)
Retained Earnings	(409.6M)	9.9B	18.8B	19.8B	19.1B	20.1B
Accounts Payable	102.3M	160M	204.1M	354M	426.7M	448.0M
Cash	1.2B	1.7B	13.9B	11.7B	9.8B	10.2B
Non Current Assets Total	651.7M	758.5M	1.4B	3.5B	3.7B	3.9B
Non Currrent Assets Other	1.0M	800K	6.5M	83.5M	36.1M	37.9M
Other Assets	2.4M	168.2M	22.2M	249.2M	286.6M	300.9M
Long Term Debt	231.0M	171.6M	176.2M	191M	214.7M	129.4M
Cash And Short Term Investments	1.3B	2.1B	14.1B	16.5B	16.8B	17.6B
Net Receivables	165.5M	12.4B	7.1B	2.2B	1.5B	2.9B
Good Will	53.7M	57.8M	61.2M	362.5M	380.6M	399.6M
Common Stock Shares Outstanding	248.5M	259.7M	249.8M	242.7M	240.4M	233.0M
Short Term Investments	137.2M	381.6M	189.4M	4.9B	7.0B	7.4B
Liabilities And Stockholders Equity	2.3B	15.8B	23.3B	23.0B	22.5B	23.7B
Non Current Liabilities Total	340.8M	455.5M	272.9M	689.9M	595.4M	409.0M
Inventory	64.1M	502.5M	439.6M	357.7M	283.4M	204.3M
Other Current Assets	89.9M	113.8M	272.3M	460M	212.6M	143.6M
Other Stockholder Equity	1.5B	1.7B	1.8B	1.2B	1.4B	993.3M
Total Liab	946.8M	3.9B	3.2B	2.8B	3.1B	1.9B
Property Plant And Equipment Gross	326.0M	594.6M	821.1M	1.2B	1.5B	1.6B
Short Long Term Debt	9.1M	129.9M	36M	28.1M	39.5M	29.7M
Total Current Assets	1.7B	15.1B	21.9B	19.5B	18.8B	9.6B
Accumulated Other Comprehensive Income	25.5M	1.8B	(846.5M)	(985.4M)	(1.3B)	(1.3B)
Non Current Liabilities Other	263.1M	18.9M	23.1M	51.9M	134.4M	141.1M
Short Term Debt	15.2M	157.8M	72M	56.2M	39.5M	46.1M
Intangible Assets	109.8M	144.6M	158.5M	804.1M	790.4M	829.9M
Common Stock	232.3M	246.3M	246.3M	248.6M	285.9M	224.2M
Property Plant Equipment	116.0M	148.1M	326.0M	520.4M	598.5M	628.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

VOO	Vanguard SP 500
XLK	Technology Select Sector
XLV	Health Care Select

Additional Tools for BioNTech Stock Analysis

When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

BioNTech Capex To Depreciation vs Ev To Sales Analysis

Capex To Depreciation vs Ev To Sales

Capex To Depreciation vs Ev To Sales Correlation Analysis

Correlation Coefficient

Capex To Depreciation

Ev To Sales

BioNTech fundamental ratios Correlations

BioNTech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

BioNTech fundamental ratios Accounts

Also Currently Popular

Additional Tools for BioNTech Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Retained Earnings	+ 1.0	Total Stockholder Equity
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 1.0	Accounts Payable
Retained Earnings	+ 0.99	Total Assets

Cash	- 1.0	Net Debt
Cash And Short Term Investments	- 0.96	Net Debt
Retained Earnings	- 0.95	Net Debt
Net Debt	- 0.94	Total Stockholder Equity
Net Debt	- 0.93	Total Assets
Total Current Assets	- 0.9	Net Debt